PALI Material Contracts | PALISADE BIO, INC.

PALISADE BIO, INC. Material Contracts

Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.

2026-06-11: Form 8-K; Exhibit 10.3; Description Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan.
2026-06-11: Form 8-K; Exhibit 10.2; Description Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan.
2026-05-12: Form 10-Q; Exhibit 10.1; Description Palisade Bio, Inc. Equity Award Policy..
2025-11-10: Form 10-Q; Exhibit 10.5; Description Form of Restricted Stock Unit Grant Notice and Award Agreement under the Palisade Bio, Inc. 2021 Equity Incentive Plan (Optional Cash Settlement)..

Filed	Form	Exhibit	Description
2026-06-11	8-K	10.3	Amended and Restated Palisade Bio, Inc. 2021 Employee Stock Purchase Plan
2026-06-11	8-K	10.2	Amended and Restated Palisade Bio, Inc. 2021 Equity Incentive Plan
2026-05-12	10-Q	10.1	Palisade Bio, Inc. Equity Award Policy.
2025-11-10	10-Q	10.5	Form of Restricted Stock Unit Grant Notice and Award Agreement under the Palisade Bio, Inc. 2021 Equity Incentive Plan (Optional Cash Settlement).
2025-11-10	10-Q	10.4	Form of Restricted Stock Unit Grant Notice and Award Agreement under the Palisade Bio, Inc. 2021 Equity Incentive Plan.
2025-11-10	10-Q	10.2	Amended and Restated Employment Agreement with Mitchell Jones, dated September 4, 2025.
2025-11-10	10-Q	10.1	Amended and Restated Employment Agreement with J.D. Finley, dated September 4, 2025.
2025-07-25	8-K	10.1	Form of Warrant Inducement Agreement
2024-12-16	8-K	10.1	Form of Warrant Amendment Agreement
2024-09-27	8-K	10.1	Form of Employment Agreement with J.D. Finley, dated September 25, 2024
2024-08-12	10-Q	10.48	Amendment to Research Collaboration and License Agreement with Giiant Pharma, Inc. dated August 2, 2024.
2024-05-03	8-K	10.3	Form of Placement Agency Agreement
2024-05-03	8-K	10.2	Form of Registration Rights Agreement
2024-05-03	8-K	10.1	Form of Securities Purchase Agreement
2024-02-01	8-K	10.1	Form of Warrant Inducement Agreement
2023-09-11	8-K	10.1	Form of Employment Agreement with Mitchell Jones, dated September 5, 2023
2023-09-11	8-K	10.2	Form of Placement Agency Agreement
2023-09-11	8-K	10.1	Form of Securities Purchase Agreement
2023-09-08	8-K	10.1	Form of Research Collaboration and License Agreement with Giiant Pharma
2023-08-10	10-Q	10.20	Palisade Bio, Inc. 2021 Inducement Incentive Plan, as Amended August 7, 2023.
2023-06-09	8-K	10.2	Palisade 2021 Employee Stock Purchase Plan, as amended
2023-06-09	8-K	10.1	Palisade 2021 Equity Incentive Plan, as amended
2023-04-05	8-K	10.3	Form of Placement Agency Agreement
2023-04-05	8-K	10.2	Form of Registration Rights Agreement
2023-04-05	8-K	10.1	Form of Securities Purchase Agreement
2023-03-22	10-K	10.36	Form of Consulting Agreement dated April 7, 2023 by and between Dr. Herbert Slade and the Company.
2023-03-22	10-K	10.35	Form of First Amendment Consulting Agreement dated January 25, 2023 by and between Dr. Herbert Slade and the Company.
2023-03-22	10-K	10.23	Non-Employee Director Compensation Policy
2023-01-04	8-K	10.3	Form of Placement Agent Agreement
2023-01-04	8-K	10.2	Form of Registration Rights Agreement
2023-01-04	8-K	10.1	Form of Securities Purchase Agreement
2022-10-14	8-K	10.1	Separation Agreement and Release with former Chief Executive Officer
2022-08-15	10-Q	10.2	First Amendment dated July 14, 2022 to the Office Lease Between AP Beacon Carlsbad, LP, and Palisade Bio, Inc., dated May 12, 2022.
2022-05-13	10-Q	10.1	Office Lease Between AP Beacon Carlsbad, LP, and Palisade Bio, Inc., dated May 12, 2022
2022-05-06	8-K	10.1	Placement Agency Agreement, dated May 6, 2022, by and between the Company and Ladenburg Thalmann & Co. Inc.
2022-05-06	8-K	10.1	Form of Securities Purchase Agreement, dated May 6, 2022, by and among the Company and the purchasers named therein
2022-03-17	10-K	10.27	Asset Transfer Agreement, by and between Alto Neuroscience, Inc. and Palisade Bio, Inc., dated October 18, 2021.
2022-03-17	10-K	10.23	Non-Employee Director Compensation Policy.
2022-03-17	10-K	10.5	License Agreement, by and between Palisade Bio, Inc. and The Regents of the University of California, dated July 6, 2021.
2021-11-23	8-K	10.6	Palisade Bio, Inc. 2021 Equity Incentive Plan, as amended.
2021-11-23	8-K	10.5	Form of Non-Employee Director Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Palisade Bio, Inc. 2021 Equity Incentive Plan.
2021-11-23	8-K	10.4	Form of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Palisade Bio, Inc. 2021 Equity Incentive Plan.
2021-11-23	8-K	10.1	Palisade Bio, Inc. 2021 Inducement Incentive Plan.
2021-05-14	10-Q	10.3	Amendment Agreement to Securities Purchase Agreement by and among, the Company, Leading BioSciences, Inc. and Altium Growth Fund, LP, dated May 3, 2021
2021-04-27	8-K	10.1	Contingent Value Rights Agreement, dated as of April 27, 2021, by and among the Company, American Stock Transfer & Trust Company, LLC and Raul Silvestre.
2021-03-18	8-K	10.1	Form of Separation Agreement
2020-12-21	8-K	10.7	Form of Leak-Out Agreement, by and between Seneca Biopharma, Inc. and the investor party thereto.
2020-12-21	8-K	10.6	Securities Purchase Agreement, by and among Seneca Biopharma, Inc., Leading BioSciences, Inc. and the investor party thereto, dated December 16, 2020.
2020-12-21	8-K	10.5	Securities Purchase Agreement, by and between Leading BioSciences, Inc. and the investor party thereto, dated December 16, 2020.
2020-12-21	8-K	10.4	Form of LBS Lock-Up Agreement.
2020-12-21	8-K	10.3	Form of Company Lock-Up Agreement.
2020-12-21	8-K	10.2	Form of LBS Support Agreement, dated as of December 16, 2020, by and between Seneca Biopharma, Inc. and each of the parties named in each agreement therein.
2020-12-21	8-K	10.1	Form of Company Support Agreement, dated as of December 16, 2020, by and between Leading BioSciences, Inc. and each of the parties named in each agreement therein.
2020-05-27	8-K	10.1	Form of Securities Purchase Agreement
2020-04-02	8-K	10.2	Employment Agreement with Matthew Kalnik, PhD
2020-04-02	8-K	10.1	Employment Agreement with Dane Saglio
2020-03-27	10-K	10.25	Amendment to Employment Agreement with Kenneth Carter effective April 1,2020
2020-01-22	8-K	10.2	Form of Placement Agent Agreement
2020-01-22	8-K	10.1	Letter Agreement dated January 17, 2020
2018-12-18	8-K	10.3	Indemnification Agreement
2018-12-18	8-K	10.2	Confidential Information and Invention Assignment Agreement
2018-12-18	8-K	10.1	Kenneth Carter Employment Agreement
2018-10-29	8-K	10.2	Form of Placement Agent Agreement
2018-10-29	8-K	10.1	Form of Securities Purchase Agreement
2018-08-09	8-K	10.1	Jim Scully Binding Term Sheet
2017-05-04	8-K	10.1	Separation Agreement and Release with former CFO
2017-03-20	8-K	10.1	Letter Agreement for Warrant Exercises
2016-11-08	10-Q	10.23	Form of Securities Purchase Agreement between Issuer and Richard Daly
2016-11-08	10-Q	10.22	Form of Securities Purchase Agreement between Issuer and Jonathan Lloyd Jones
2016-09-12	8-K	10.1	Securities Purchase Agreement.
2016-06-16	8-K	10.1	Form of Amendment to General Release and Waiver of Claims Agreement between Neuralstem and I. Richard Garr
2016-05-13	8-K	10.1	Form of Securities Purchase Agreement.
2016-03-04	8-K	10.1	General Release and Waiver of Claims
2016-02-19	8-K	10.2	Confidential Information and Invention Assignment Agreement
2016-02-19	8-K	10.1	Richard Daly Employment Agreement
2015-11-16	8-K	10.1	Form of Indemnification Agreement
2015-05-11	8-K	10.1	Offer Letter between Neuralstem, Inc. and Jonathan Lloyd Jones
2015-03-02	8-K	10.1	EMPLOYMENT AGREEMENT AMENDMENT
2014-10-29	8-K	10.1	Form of Second Amendment dated October 28, 2014
2014-09-18	8-K	10.1	Form of Employment Agreement Amendment of Dr. Karl Johe
2014-03-10	10-K	10.13	Form of Outside Director Agreement
2014-01-06	8-K	10.1	Form of Securities Purchase Agreement
2013-10-25	8-K	10.1	At The Market Offering Agreement
2013-09-10	8-K	10.1	Form of Securities Purchase Agreement
2013-03-27	8-K	10.2	Form of Intellectual Property and Security Agreement
2013-03-27	8-K	10.1	Form of Loan and Security Agreement dated
2012-07-27	8-K	10.3	Form of Renewal Agreement of Dr. Tom Hazel
2012-07-27	8-K	10.2	Form of Renewal Agreement of Dr. Karl Johe
2012-07-27	8-K	10.1	Form of Renewal Agreement of I. Richard Garr
2012-02-08	8-K	10.1	Form of Securities Purchase Agreement
2011-03-16	10-K	10.7	Consulting Agreement dated January 2010 between Market Development Consulting Group and the Company and amendments No. 1 and 2.
2010-10-05	10-K/A	10.5	Employment Agreement with Thomas Hazel, Ph.D. dated August 11, 2008
2010-07-14	8-K	10.1	2010 Equity Compensation Plan
2010-06-29	8-K	10.1	Form of Securities Purchase Agreement
2009-07-01	8-K	10.1	Form of Securities Purchase Agreement
2009-03-31	10-K	10.4	Amended terms to the Employment Agreement of Karl Johe dated January 1, 2009
2009-03-31	10-K	10.2	Amended terms to the Employment Agreement of I Richard Garr dated January 1, 2008

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
FATE THERAPEUTICS INC (FATE)	United States	$0.280B	-2.51
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
Liminatus Pharma, Inc. (LIMN)	United States	$0.282B
SUTRO BIOPHARMA, INC. (STRO)	United States	$0.260B	-3.05
Inhibikase Therapeutics, Inc. (IKT)	United States	$0.296B	-4.44
X4 Pharmaceuticals, Inc (XFOR)	United States	$0.297B	-4.99
SAB Biotherapeutics, Inc. (SABS)	United States	$0.306B	-25.49
Century Therapeutics, Inc. (IPSC)	United States	$0.306B	-4.02
Lineage Cell Therapeutics, Inc. (LCTX)	United States	$0.241B	-10.35